BRIEF published on 12/09/2024 at 14:10, 21 days 4 hours ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
PRESS RELEASE published on 12/09/2024 at 14:05, 21 days 5 hours ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 25 days 6 hours ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 25 days 6 hours ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 month 2 days ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 month 2 days ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 month 15 days ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 month 15 days ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 month 17 days ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 month 17 days ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
Published on 12/30/2024 at 18:00, 1 hour 8 minutes ago Trust Consulting Services AI Center of Excellence Shifts Focus to Digital Workforce Development in 2025
Published on 12/30/2024 at 17:00, 2 hours 8 minutes ago Levity Products to Join Arab Health Expo 2025
Published on 12/30/2024 at 15:00, 4 hours 8 minutes ago Western Alaska Minerals Announces Grant of Options and Restricted Share Units
Published on 12/30/2024 at 14:30, 4 hours 38 minutes ago Abasca Resources Engages Understood Mineral Resources Ltd. to Complete Flake Graphite Resource Estimate of its Loki Flake Graphite Zone and Grants Stock Options
Published on 12/30/2024 at 13:00, 6 hours 8 minutes ago SMX is Redefining Ethical Sourcing, KYC, and Data Security in a Tech-Driven World of Fashion and Electronics
Published on 12/30/2024 at 17:45, 1 hour 23 minutes ago Eighteenth acquisition in 2024: Mutares has signed an agreement to acquire Nervión Industries, Engineering and Services, S.L.U. from Amper S.A.
Published on 12/30/2024 at 16:50, 2 hours 18 minutes ago EQS-Adhoc: OTI Greentech AG: Resignation of the chair of the supervisory board
Published on 12/30/2024 at 16:16, 2 hours 51 minutes ago EQS-Adhoc: OTI Greentech AG: Application for delisting from the open market of the Düsseldorf Stock Exchange resolved
Published on 12/30/2024 at 15:56, 3 hours 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 12/30/2024 at 15:55, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spirent Communications plc
Published on 12/30/2024 at 18:15, 53 minutes ago Icade - PR - Binding agreement signed between Icade and Casino
Published on 12/30/2024 at 17:45, 1 hour 23 minutes ago Disclosure of trading in own shares from December 23th, 2024, to December 27th, 2024. Detailed information per transaction
Published on 12/30/2024 at 17:45, 1 hour 23 minutes ago Disclosure of trading in own shares from December 23th, 2024, to December 27th, 2024
Published on 12/27/2024 at 14:50, 3 days 4 hours ago ENGIE awarded a 250 MW floating offshore wind project in the French Mediterranean Sea
Published on 12/27/2024 at 08:49, 3 days 10 hours ago Completion of the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders
